ST316
- Generic Name
- ST316
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- Colon CancerMetastatic Colon Cancer
- Interventions
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Sapience Therapeutics
- Target Recruit Count
- 115
- Registration Number
- NCT05848739
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Westchester Medical Center, Valhalla, New York, United States
🇺🇸Fred Hutch Cancer Center, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath